1. Home
  2. WNW vs SCYX Comparison

WNW vs SCYX Comparison

Compare WNW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WNW
  • SCYX
  • Stock Information
  • Founded
  • WNW 2015
  • SCYX 1999
  • Country
  • WNW China
  • SCYX United States
  • Employees
  • WNW N/A
  • SCYX N/A
  • Industry
  • WNW Catalog/Specialty Distribution
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • WNW Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • WNW Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • WNW 49.2M
  • SCYX 50.3M
  • IPO Year
  • WNW 2020
  • SCYX 2014
  • Fundamental
  • Price
  • WNW $1.64
  • SCYX $1.00
  • Analyst Decision
  • WNW
  • SCYX Buy
  • Analyst Count
  • WNW 0
  • SCYX 1
  • Target Price
  • WNW N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • WNW 355.2K
  • SCYX 174.1K
  • Earning Date
  • WNW 12-24-2024
  • SCYX 11-06-2024
  • Dividend Yield
  • WNW N/A
  • SCYX N/A
  • EPS Growth
  • WNW N/A
  • SCYX N/A
  • EPS
  • WNW N/A
  • SCYX N/A
  • Revenue
  • WNW $380,345.00
  • SCYX $8,566,000.00
  • Revenue This Year
  • WNW N/A
  • SCYX N/A
  • Revenue Next Year
  • WNW N/A
  • SCYX $405.82
  • P/E Ratio
  • WNW N/A
  • SCYX N/A
  • Revenue Growth
  • WNW N/A
  • SCYX N/A
  • 52 Week Low
  • WNW $0.71
  • SCYX $1.06
  • 52 Week High
  • WNW $11.11
  • SCYX $3.07
  • Technical
  • Relative Strength Index (RSI)
  • WNW 75.09
  • SCYX 37.92
  • Support Level
  • WNW $0.91
  • SCYX $1.06
  • Resistance Level
  • WNW $1.68
  • SCYX $1.25
  • Average True Range (ATR)
  • WNW 0.15
  • SCYX 0.07
  • MACD
  • WNW 0.05
  • SCYX -0.01
  • Stochastic Oscillator
  • WNW 78.63
  • SCYX 17.65

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments: Clean Food Platform; Restaurant; and Others. The company generates the majority of its revenue from Technical services.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: